U.S. Markets closed

Steven Cohen Buys Trillium Therapeutics and Boosts Stake in Smith & Wesson Corp

After Steven Cohen (Trades, Portfolio) of Point72 (formerly SAC Capital Advisors) started a new position in Conn's Inc. (CONN) on April 21, he started a new position in Trillium Therapeutics Inc. (TRIL) and boosted his stake in Smith & Wesson Holding Corp (SWHC) on April 22.


Trillium Therapeutics Inc. (TRIL)

Cohen purchased 378,050 shares of Trillium Therapeutics, which equals 5.6% of shares outstanding. Year to date, the stock's price has gained 146% to close at $22.16 per share on Thursday.

Trillium Therapeutics develops cancer therapies. Stem Cell Therapeutics Corp. was incorporated under the Business Corporations Act (Alberta) on March 31, 2004, as Neurogenesis Biotech Corp. Trillium Therapeutics Inc. has a market cap of $98.300 million; its shares were traded at around $22.16.

Smith & Wesson Holding Corp (SWHC)

Cohen boosted his stake in Smith & Wesson Holding by 187.2% to 2,698,899 shares from 939,691 shares held at the end of the fourth quarter. After the increase, the holding represents 5% of the company.

Smith & Wesson is a gun and firearm manufacturing company. Smith & Wesson Holding Corp is a Nevada corporation. Smith & Wesson Holding Corp has a market cap of $801.60 million; its shares were traded at around $14.91 with a P/E ratio of 16.0 and P/S ratio of 1.5.

For more stock trades of gurus in real time, visit GuruFocus' Real Time Picks, a Premium Feature. Not a Premium Member of GuruFocus? Try it free for 7 days here.

This article first appeared on GuruFocus.